Application of host cell CXCR6 gene as an anti-flavivirus target in the preparation of anti-flavivirus drugs
By downregulating CXCR6 gene expression in host cells and using specific siRNA sequences to inhibit the replication and infection of flaviviruses, the problem of lack of effective treatment for flavivirus infection is solved, effective control of flaviviruses and reducing the virus in host cells risk of replication and infection.
Patent Information
- Application Number
- CN202411083918.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-08
AI Technical Summary
The lack of effective treatments for the treatment of diseases caused by flaviviruses, such as dengue fever, West Nile disease and Zika virus, especially due to the general lack of effective treatments for flavivirus infection, which poses serious threats to human health. .
By using the host cell CXCR6 gene as a target for antiflaviviruses, CXCR6 gene inhibitors, such as siRNA, shRNA, dsRNA, miRNA, cDNA, antisense RNA/DNA, low-molecular compounds and peptides, to inhibit the replication of flaviviruses, etc., to develop CXCR6 gene inhibitors, such as siRNA, shRNA, dsRNA, miRNA, cDNA, antisense RNA/DNA, low-molecular compounds and peptides, to inhibit the replication of flaviviruses. and infection. Specific methods include blocking the entry and replication of flavivirus by downregulating the CXCR6 protein expression level using the siRNA sequences 5'-GUUUCAUUGUGUGGUUAA-3' and 5'-UUAACCACUACAUGAAAC-3', etc.
Effectively downregulate the expression level of the host CXCR6 protein and inhibit the replication and infection of flaviviruses, providing a new effective means to treat flavivirus infection, significantly reducing the adsorption and replication levels of viruses, prolonging the survival of infected mice, and reducing Virus-induced brain tissue damage.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, in particular to the application of host cell CXCR6 gene as an anti-flavivirus target in the preparation of anti-flavivirus drugs. Background Art
[0002] Flaviviruses include more than 70 species, including ZIKV, DENV, West Nile virus (WNV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV), of which about 40 are related to human diseases.
[0003] Dengue fever is an acute infectious disease caused by DENV. With global climate change and increased population density, dengue fever epidemic areas have gradually expanded, involving 112 countries and regions in Southeast Asia, America, Africa, and the Western Pacific. Dengue fever has gradually evolved from a sporadic disease to a public health problem with significant social and economic impacts, posing a serious threat to human health. West Nile disease is an acute zoonotic infectious disease caused by WNV, which can cause West Nile fever and West Nile viral meningitis and encephalitis. WNV is mainly distributed in Africa, the Middle East, Eurasia, Australia, and the Americas, and the incidence and mortality of WNV are increasing year by year. Japanese encephalitis, also known as Japanese encephalitis, is an acute zoonotic infectious disease caused by JEV that mainly damages the central nervous system. The disease is mainly distributed in Asia and the Pacific. The mortality rate of Japanese encephalitis can reach 35%, and nearly half of the survivors have sequelae such as neuromotor and behavioral disorders to varying degrees. ZIKV is the pathogen of human Zika virus disease. Since there is generally a lack of effective treatments for flavivirus infections, it is currently an extremely important and urgent task to strengthen research on the mechanisms of flavivirus infection and discover new targets for anti-flavivirus drugs.
[0004] CXC chemokine receptor type 6 (CXCR6), also known as STRL33, Bonzo or TYMSTR, belongs to the G protein-coupled receptor superfamily and has seven α-helical transmembrane regions. CXCR6 is highly expressed in tissues such as the placenta, spleen, and thymus. As a receptor protein, CXCR6 mediates the entry of HIV and SIV into host cells. Summary of the invention
[0005] The purpose of the present invention is to provide the use of a host cell CXCR6 gene inhibitor in the preparation of an anti-flavivirus drug.
[0006] In order to achieve the purpose of the present invention, in the first aspect, the present invention provides the use of host cell CXCR6 gene as an anti-flavivirus target in the preparation of an anti-flavivirus drug.
[0007] In the present invention, the reference sequence number of the CXCR6 gene in NCBI is NP_001373364.1.
[0008] In a second aspect, the present invention provides use of a CXCR6 gene inhibitor in the preparation of an anti-flavivirus drug.
[0009] Furthermore, the flavivirus includes but is not limited to Zika virus (ZIKV) and dengue virus (DENV).
[0010] In a third aspect, the present invention provides an anti-flavivirus drug, the active ingredient of which is a CXCR6 gene inhibitor.
[0011] Furthermore, the inhibitor may be selected from at least one of shRNA, siRNA, dsRNA, miRNA, cDNA, antisense RNA / DNA, low molecular weight compounds, peptides, antibodies and the like.
[0012] Preferably, the inhibitor is siRNA, the sequence of which is:
[0013] 5'-GUUUCAUUGGUAGGUUAA-3' (SEQ ID NO:1)
[0014] 5'-UUAACCACUACAAUGAAAC-3' (SEQ ID NO:2)
[0015] In a fourth aspect, the present invention provides the use of CXCR6 gene as an anti-flavivirus target.
[0016] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects:
[0017] The present invention provides a new anti-flavivirus target, which inhibits the replication of flavivirus by downregulating the expression level of host CXCR6 protein, and blocks flavivirus infection by knocking out the CXCR6 gene. Compounds, peptides or antibodies can be used to inhibit flavivirus infection by targeting the host cell CXCR6 receptor protein, providing an effective means for treating flavivirus infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 In a preferred embodiment of the present invention, siRNA is used to downregulate the expression of endogenous CXCR6 to inhibit the replication of ZIKV in Bewo cells. .
[0019] Figure 2This is a preferred embodiment of the present invention in which siRNA is used to downregulate the expression of endogenous CXCR6 to inhibit the adsorption of ZIKV and DENV. (A) Different lineages of ZIKV; (B) DENV-2; (C) EV71. .
[0020] Figure 3 This is the effect of knocking out or overexpressing CXCR6 on the adsorption of ZIKV and DENV-2 in a preferred embodiment of the present invention. .
[0021] Figure 4 This is the specific sequence of the △CXCR6 cell gene deletion in the preferred embodiment of the present invention.
[0022] Figure 5 The CXCR6- / - knockout in the preferred embodiment of the present invention inhibits brain tissue damage and mouse death caused by ZIKV. (A) Brain tissue of suckling mice; (B) Pathological detection of brain tissue of suckling mice; (C) ZIKV RNA levels in brain tissue of suckling mice at different time points of infection; (D) Statistics of survival of suckling mice infected with different lineages of ZIKV, DENV, and EV71. .
[0023] Figure 6 The results of the siRNA sequence screening experiment in the preferred embodiment of the present invention are shown.
[0024] Figure 7 This is the result of the CRISPR-Cas9-CXCR6 sgRNA sequence screening experiment in a preferred embodiment of the present invention. DETAILED DESCRIPTION
[0025] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.
[0026] Example 1 siRNA silencing of endogenous CXCR6 inhibits ZIKV replication in human cells
[0027] In this example, siCXCR6 (SEQ ID NO: 1-2) was used to silence the expression of CXCR6 in Bewo cells, and the final concentration of siRNA transfection in Bewo cells was 50 nM (two siRNAs were co-transfected, and the final concentration was 50 nM).
[0028]
[0029] ZIKV (MOI = 0.5) was infected 48 hours after transfection, and cells were collected 48 hours after infection to detect the replication level of ZIKV in cells. Figure 1As shown in the figure, when cell CXCR6 was knocked down by about 50%, the replication level of ZIKV mRNA also decreased by about 50%. Western blot analysis of cell samples showed that after CXCR6 was knocked down, the protein level of the virus decreased significantly. This result further confirmed that reducing CXCR6 expression in human Bewo cells can inhibit the replication of ZIKV in cells.
[0030] Example 2 siRNA silencing CXCR6 expression inhibits ZIKV and DENV intracellular replication
[0031] CXCR6 is distributed in the cell membrane, so we speculate that CXCR6 affects the ZIKV adsorption process. siRNA was used to reduce the level of CXCR6 in Bewo cells. ZIKV or DENV was added to the cells 24 hours after siRNA transfection. The cells were placed at 4 ℃. After 1 hour, PBS was used to wash away the unadsorbed virus particles. After 48 hours of infection, the expression levels of viral mRNA and protein in the cells were detected. A control was set up, with EV71 as the control virus group. The results are shown in Figure 2 As shown in the figure, compared with the NC control group, the expression of CXCR6 was downregulated, and the mRNA level of ZIKV (MR766 is an African lineage, H / PF / 2013 and PLCal / 2015 are both Asian lineages) or DENV in the cell was downregulated by more than 90%, and the protein of the virus also decreased significantly. EV71 belongs to the genus Enterovirus of the Picornaviridae family. EV71 has great differences from ZIKV in terms of virus infection mode. The results of the EV71 group showed that the expression of CXCR6 in the cell was downregulated, and the mRNA level and protein level of the EV71 infection group did not change significantly compared with the NC control group. This result shows that CXCR6 plays an important role in the adsorption process of ZIKV and DENV.
[0032] Example 3 Knockout of CXCR6 blocks ZIKV and DENV-2 adsorption
[0033] Flow cytometry is a classic experiment for detecting changes in cell surface protein content. We used flow cytometry to verify the effect of CXCR6 expression levels on the ZIKV adsorption process. Bewo-CXCR6WT (control), Bewo-CXCR6KO (△CXCR6), and Bewo-CXCR6KO overexpressing CXCR6 mutant plasmid (△CXCR6+CXCR6) were infected with ZIKV or DENV-2 (MOI=20) at 4°C for 1 hour. After infection, the cells were rinsed with PBS, and the ZIKV E protein or DENV-2 E protein adsorbed on the cell surface virus particles was specifically labeled with antibodies and detected by flow cytometry. The results are shown in Figure 3As shown in the figure, compared with Bewo-CXCR6WT (control) cells, when CXCR6 was knocked out in cells, ZIKV and DENV-2 could no longer adsorb to the cell surface. When CXCR6 was overexpressed in Bewo-CXCR6KO (△CXCR6), the adsorption of ZIKV and DENV-2 was increased. At the same time, we selected EV71 virus as a control. The results show that knocking out or overexpressing CXCR6 in Bewo cells does not affect the adsorption process of EV71.
[0034] △CXCR6 cells are monoclonal cell lines in which the CXCR6 gene is knocked out in wild-type Bewo cells using CRISPR-Cas9 technology. The cell line construction process is as follows: Construction of a specific targeted human CXCR6 The sgRNA plasmids of the gene (CXCR6 sgRNA-1: 5′-catatgtggttaccatgacg-3′, SEQ ID NO:3; CXCR6 sgRNA-2: 5′-tgacgaggcaatttccactg-3′, SEQ ID NO:4) were used. HEK293T cells were seeded in 6-well plates with a cell density of 2.5×10 5 / mL, and co-transfected with lentiviral packaging plasmid and core plasmid after 24h of culture, 500ng pMD2.G, 500ng pSPAX2 (plasmids pMD2.G and pSPAX2 were purchased from Addgene) and 2μg CRISPR / Cas9-CXCR6 (mixed in an equal molar ratio by a plasmid carrying sgRNA-1 and expressing Cas9 protein and a plasmid carrying sgRNA-2 and expressing Cas9 protein), and the lentivirus was harvested 48h after transfection. Bewo cells were seeded in 6-well plates at a cell density of 3×10 per well. 5 / mL, 1mL of lentivirus was added to each well for infection after 24h of culture, and fresh culture medium was replaced 12h after infection to complete lentiviral transduction. Bewo cells were infected with the above-packaged lentivirus, and 48h after infection with the lentivirus, the complete culture medium containing puromycin (final concentration of 2μg / mL) was replaced for selective culture. The cell medium was changed every 2 days to obtain the Bewo-CXCR6KO polyclonal cell line. The polyclonal cell line was monoclonalized to obtain a Bewo cell line with complete knockout of the CXCR6 gene, named BewoKO (△CXCR6).
[0035] Construction of △CXCR6+CXCR6 mutant plasmid: that is, the construction of a plasmid that can overexpress CXCR6 protein in Bewo cells with CXCR6 knockout. We used a genome extraction kit to extract genomic DNA from the △CXCR6 cell line and used primers to specifically amplify a fragment of about 100 bp upstream and downstream of CXCR6 sgRNA (F: 5′-aaggccaccaaggcctacaaccagcaag-3′; R: 5′-gaagcctccagcatgaagcagtgttttg-3′). The PCR product fragments were sequenced and finally determined. CXCR6 Gene knockout sequences. Figure 4 The specific sequence of the △CXCR6 cell gene deletion is shown. Synonymous mutations were performed on the PAM sequence of the sgRNA and the sgRNA region sequence to obtain a plasmid that can overexpress CXCR6 in the knockout cell line.
[0036] Example 4 CXCR6- / - knockout inhibits ZIKV-induced brain tissue damage and mouse death
[0037] Using C57B / 6J mice, the CXCR6 gene in mice was knocked out by CRISPR-Cas9 technology (CXCR6 knockout mice were purchased from Shanghai Model Organisms). 7-day-old suckling mice were injected intracranially with ZIKV (10 PFU) (CXCR6-KO group), and wild-type mice were set as the control group (CXCR6-WT). 14 days after infection, suckling mice were dissected and changes in brain size were recorded. ZIKVE21K strain can cause severe brain tissue damage. Results Figure 5 (A) shows that CXCR6 knockout inhibited the reduction of brain tissue caused by E21K strain, and the results of pathological sections Figure 5 (B) also showed that knocking out CXCR6 reduced brain tissue atrophy caused by virus infection. ZIKV mRNA in brain tissue was measured. Figure 5 (C) shows that 11-day-old mice were infected with ZIKV, and the ZIKV RNA level in the CXCR6-KO group was significantly reduced compared with the control CXCR6-WT group.
[0038] CXCR6- / - knockout mice (7 days old) were intracranially infected with ZIKV or DENV (10 PFU), and EV71 was used as the control group (2E5 PFU). Figure 5 As shown in (D), knocking out CXCR6 prolonged the survival rate of ZIKV and DENV infected suckling mice, but had no significant effect on the survival of EV71 infected mice. The above results indicate that CXCR6 plays a key role in the in vivo infection process of ZIKV and DENV.
[0039] Example 5 siRNA sequence screening experiment
[0040] According to the CXCR6 gene sequence, the following candidate siRNA sequences were designed:
[0041] Combination 1: si CXCR6(H)-463
[0042] 5'-GCAUCACUGUGGAUCGUUU-3'
[0043] 5'-AAACGAUCCACAGUGAUGC-3'
[0044] Combination 2: si CXCR6(H)-859
[0045] 5'-GCAGCACACACUGGGAAUA-3'
[0046] 5'-UAUUCCCAGUGUGUGCUGC-3'
[0047] Combination 3: si CXCR6(H)-973
[0048] 5'-GCCUGAAGUUUCGAAAGAA-3'
[0049] 5'-UUCUUUCGAAACUUCAGGC-3'
[0050] NC Group:
[0051] 5'-UUCUCCGAACGUGUCACGU-3'
[0052] 5'-ACGUGACACGUUCGGAGAA-3'
[0053] Bewo cells were transfected with siRNA (i.e., two siRNAs in each group were co-transfected, and the final concentration of each siRNA was 50 nM). Total RNA was extracted from cells 24 hours after transfection, and qRT-PCR was used to determine the level of CXCR6 knockdown by each siRNA. The results are shown in Figure 6 .
[0054] The results showed that compared with the NC group, the CXCR6 levels in the si CXCR6(H)-463 and si CXCR6(H)-859 groups were not significantly downregulated. However, the CXCR6 mRNA level in the si CXCR6(H)-973 group was downregulated by about 50%, and the two siRNA combinations of Scheme 3 were finally selected.
[0055] Example 6 CRISPR-Cas9-CXCR6 sgRNA sequence screening experiment
[0056] For the CXCR6 gene sequence, the following sgRNA sequence was designed:
[0057] sgRNA-1: 5'-CATATGTGGTTACCATGACG-3'
[0058] sgRNA-2: 5'-TGACGAGGCAATTTCCACTG-3'
[0059] sgRNA-3: 5'-TTTCAATGACAGCAGCCAGG-3'
[0060] sgRNA-4: 5'-TCTGCCCTGCATGTACCTGG-3'
[0061] Transient transfection of CRISPR-Cas9-CXCR6 sgRNA plasmids in cells was performed to determine the effective plasmids that can downregulate endogenous CXCR6 in cells. Bewo cells were transfected and cells were harvested 48 hours after transfection. Western blot was performed to detect the transient knockdown efficiency of each plasmid. The results are shown in Figure 7 The sgRNA-1 and sgRNA-2 co-transfection group significantly downregulated the endogenous CXCR6 expression in cells, and the sgRNA-1 and sgRNA-2 co-transfection group was finally selected.
[0062] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. Application of CXCR6 gene inhibitors in the preparation of anti-flavivirus drugs; The reference sequence number of the CXCR6 gene in NCBI is NP_001373364.1; The inhibitor is siRNA, consisting of 5'- GCCUGAAGUUUCGAAAGAA-3' and 5'- UUCUUUCGAAACUUCAGGC -3'; The flavivirus is selected from Zika virus and dengue virus.
2. An anti-flavivirus drug, characterized in that: The active ingredient is a CXCR6 gene inhibitor; The reference sequence number of the CXCR6 gene in NCBI is NP_001373364.1; The inhibitor is siRNA, consisting of 5'- GCCUGAAGUUUCGAAAGAA-3' and 5'- UUCUUUCGAAACUUCAGGC -3'; The flavivirus is selected from Zika virus and dengue virus.
